Therapeutic monoclonal antibodies continue to achieve clinical success for the treatment of many different diseases, particularly cancer. However, the production and purification of antibodies continues to be a time and labor-intensive process with considerable technical challenges. Gene-based delivery of antibodies may address this, via direct production within the host that achieves therapeutic levels. In this report, we validate the feasibility that gene-based delivery is a viable approach for efficacious delivery of antibodies in the preclinical and, presumably, clinical setting. We demonstrate high and sustained in vivo expression of the murine antihuman epidermal growth factor receptor antibody 14E1 following intramuscular delivery by adeno-associated virus (AAV) 2/1. Incorporating the Furin/2A technology for monocistronic expression of both heavy and light chains, we achieved sustained serum levels of full-length 14E1 peaking over 1 mg ml À1 in athymic nude mice. In the A431 xenograft tumor model, 14E1
Introduction
Therapeutic monoclonal antibodies (mAbs) have made a significant impact on the treatment of many different diseases including autoimmune disorders, infectious diseases and cancer. mAbs possess advantages over other forms of therapeutics including the capacity to distinguish and bind antigens with high affinity as well as the ability to recruit immune responses via the Fc domain. 1, 2 To date, 23 mAb therapeutics have been approved and are now on the market. Well over 150 candidate mAbs are currently in various stages of clinical development worldwide, further emphasizing the increasing presence of mAbs as therapeutic agents. 3 The emergence of technological advances such as phage display have significantly improved capabilities to discover and develop novel antibodies. However, the production of antibodies for both preclinical and clinical functions continues to be a bottleneck for antibody therapeutics. [4] [5] [6] [7] The expression and purification of sufficient amounts of candidate antibodies required for preclinical in vivo validation studies can often be a labor, time and cost-intensive process. 4, 5, [8] [9] [10] For most antibody therapies in the clinic, delivery requires lengthy infusions of large amounts of antibody. This can result in suboptimal systemic levels and may create considerable side effects for the patient. 4, 7, 11 Particularly for the treatment of chronic disease such as cancer, high and sustained antibody levels often in the range of several hundreds of mgs per milliliter are required for therapeutic efficacy. 12 As an alternative to conventional methods, a gene-based delivery approach could expedite antibody delivery by bypassing in vitro expression and purification and advancing directly into antibody production in vivo.
There have been a variety of efforts to deliver efficacious levels of full-length antibodies in in vivo cancer models via gene-based delivery. 13, 14 Nonviral forms of delivery, particularly plasmid injection/electroporation, have successfully delivered functional full-length antibodies but have not yet approached the serum antibody levels required for efficacy. 12, 15, 16 Recent delivery of an anti-HER2 antibody by adenovirus showed significant inhibition of tumor growth; however, expression of the antibody was relatively transient likely due to immunogenicity and levels in the serum rapidly decreased. 17 Consequently, additional approaches are needed if genebased delivery of mAbs is to realize its clinical potential.
Recognized for distinct advantages including long-term expression and low immunogenicity, adeno-associated virus (AAV) is an appealing gene-delivery vector. 13, 18, 19 A problematic limiting factor for AAV delivery of a full-length antibody has been the packaging capacity of the vector. Packaging efficiency of AAV significantly decreases once the size of the insert extends beyond B5 kb. 20 Recently, Fang et al. 21 developed a novel Furin/2A sequence allowing for the monocistronic expression of a full-length antibody by AAV8. The Furin/2A sequence enabled the antibody expression cassette to package efficiently in AAV and allowed for equimolar expression of both heavy and light chains. 21 Incorporating the Furin/ 2A technology in their AAV vector, the authors achieved high (peak levels 41000 mg ml
À1
) and stable (4140 days) serum levels of a full-length antibody for significant antitumor efficacy. 21 Adapting the Furin/2A technology in an AAV2/1 vector, we were able to achieve high and stable serum levels peaking at over 1000 mg ml À1 in athymic mice for the full-length murine antihuman epidermal growth factor receptor (EGFR) antibody 14E1. We were able to demonstrate that this systemic expression of 14E1 was capable of inhibiting growth of an A431 xenograft tumor if administered prior to tumor challenge. More importantly, significant inhibition of tumor growth was noted in an established tumor model, which we believe is the first report of growth inhibition of an established tumor by a full-length antibody following delivery by AAV.
Materials and methods

Construction of recombinant plasmids
Total RNA was extracted from the previously developed 14E1 hybridoma cell line, 22 using the RNEasy kit (Qiagen, Valencia, CA). The isolated RNA was used in a reverse transcription reaction with the Sprint Powerscript Pre-primed Single Shots (BD Biosciences, San Jose, CA) to synthesize the first-strand cDNA. The first-strand cDNA served as the template for separate PCR reactions (Phusion Hot Start kit, Finnzymes, Espoo, Finland) amplifying the 14E1 immunoglobulin G (IgG) 1 heavy and the k-light chain. The heavy chain was amplified using the MuIgV H 5 0 -B forward primer from the Mouse Ig-Primer Set (EMD Biosciences, San Diego, CA). A custom reverse primer, GER222 (Table 1) , was used for the conserved 3 0 end. All custom primers used in this study were synthesized by Midland Certified Reagent Company (Midland, TX). The light chain was amplified using the MuIgkV L 5 0 -F forward primer from the Mouse Ig-Primer Set (EMD Biosciences) and the custom reverse primer was GER223 (Table 1) . Both heavy and light chain PCR products were then separately cloned into the pCR2.1-TOPO vector using the TA cloning kit (Invitrogen, Carlsbad, CA). Sequencing was performed on heavy and light chain clones to verify the correct sequence. 22 Construction of 14E1 Etag -pZAC2. 1 The heavy and light chain of 14E1 were PCR amplified using primers to introduce a linker coding for the Furin/ 2A peptide sequence between the heavy and light chain. For the heavy chain, the GER233 and GER234 primers were used in the PCR (Table 1 ). The reverse primer GER234 introduced the front portion of the Furin/2A sequence. For the light chain, the GER235 and GER236 primers were used in the PCR (Table 1 ). The forward primer GER235 introduced the back portion of the Furin/2A sequence. The heavy and light chain PCR products were both ligated to the pZAC2.1 AAV shuttle vector in a three-way ligation. The complete sequence coding for the Furin/2A peptide sequence was formed by this ligation. This intermediate construct contained the 14E1 heavy and light chain separated by the Furin/2A sequence in pZAC2.1. The coding sequence was cloned downstream of the CMV promoter on the pZAC vector. The vector includes an SV40 poly A sequence at the end of the coding sequence. This entire expression cassette is flanked by the inverted terminal repeats (ITRs) of AAV2. The Etag motif was subsequently introduced into the 14E1-pZAC2.1 construct by the ligation of an oligonucleotide adaptor. Complementary oligo primers (GER241 and GER242, Table 1 ) coding for the Etag and the front portion of the F2A peptide motif were custom synthesized. The primers were denatured by a Figure 1c ). The heavy chain fragment included a StuI site at the 5 0 end and a BamHI site at the 3 0 end (Figure 1b) . The light chain fragment included a BamHI site at the 5 0 and a BclI site at the 3 0 end (Figure 1b) . The 14E1 Etag -pZAC2.1 construct was linearized by a StuI/BclI double digest dropping out a 1.9 kb fragment containing the majority of the heavy chain, the entire Etag, the entire F/2A sequence and the majority of the light chain (Figure 1b) . This linearized construct served as the backbone. To complete 14E1A Etag -pZAC2.1, three additional fragments were needed. Two of these fragments were the ablated heavy and light chain CDR3 fragments (Figure 1b) . The final fragment was the sequence between the BamHI site on the heavy chain and BamHI site on the light chain (Figure 1b) . The process to bring together the four pieces of the 14E1A Etag -pZAC2.1 construct was executed in two steps. First, the heavy-and light-ablated CDR3 fragments were ligated into the linearized pZAC2.1 vector by a three-way ligation in which the 5 0 StuI site of the heavy fragment and the 3 0 BclI site of the light fragment ligated to their respective sites on the linearized pZAC2.1 vector. The BamHI/BamHI fragment encoding the antibody sequence between the CDR3 regions was then introduced by a second ligation step to complete the full construct.
Production of adeno-associated virus2/1 DNA for 14E1 Etag -pZAC and 14E1A Etag -pZAC were transformed into Stbl2 competent Escherichia coli cells (Invitrogen) and purified using plasmid DNA endotoxinfree giga purification kits (Qiagen). Purified DNA was submitted to Vector Core (University of Pennsylvania, Philadelphia, PA) for production of single-stranded rAAV2/1-14E1 and rAAV2/1-14E1A. This serotype 2/1 AAV was used throughout this study.
Cell culture A431 human vulvar carcinoma cells were cultured in Dulbecco's modified Eagle's medium (DMEM; Invitrogen) supplemented with 3 M L-glutamine and 10% heatinactivated fetal bovine serum at 10% CO 2 and 37 1C in a humidified incubator. 293F Freestyle (Invitrogen) cells were cultured in suspension with serum-free 293 Freestyle Media (Invitrogen) at 10% CO 2 and 37 1C in a humidified incubator.
Antibody expression and purification
For in vitro expression of 14E1 and 14E1A antibodies, 293F cells (Invitrogen; density of 1 Â 10 6 cells per ml) were transfected with either 14E1 Etag -pZAC2.1 or 14E1A EtagpZAC2.1 plasmid DNA using Lipofectamine 2000 reagent (Invitrogen). At 72 h after the beginning of the transfection, the supernatant was removed and filtered using 0.45 mM nitrocellulose filter. The 14E1 and 14E1A antibodies were purified from 293F cell supernatant by affinity chromatography with an anti-Etag column (GE Healthcare, Piscataway, NJ). Nitrocellulose-filtered 293 supernatant (0.22 mm) was first dialyzed against three volumes of phosphate-buffered saline (PBS) and concentrated, then loaded onto the column. The Etag column was then washed with sodium acetate buffer (50 mM NaOAc, 140 mM NaCl, pH6.5) and then a high-salt buffer (50 mM NaOAc, 1 M NaCl, pH6.5) to remove nonspecifically bound impurities. Specifically bound antibody was eluted by a low-pH sodium acetate buffer Established tumor inhibited by a-EGFR Ab from AAV DT Ho et al (50 mM NaOAc, 140 mM NaCl, pH 3.0) and immediately neutralized with 1 N NaOH to a pH of 6.5. Confirmation of purity, approximate molecular weight and state of aggregation was routinely determined for full-length antibody using a TSKgel G3000 SW XL 7.8 mm Â 30 cm 5 mm column (TOSOH Bioscience, LLC, Japan) with an isocratic buffer of 200 mM potassium phosphate, 150 mM potassium chloride, pH 6.8, and a flow rate of 0.5 ml min À1 (data not shown).
Western blot analysis Samples were separated under reducing and nonreducing conditions by SDS-polyacrylamide gel electrophoresis (PAGE) using 4-12% NuPAGE gels (Invitrogen) and subsequently transferred on to nitrocellulose membranes using the iBlot system (Invitrogen). Samples were reduced using a final concentration of 100 mM DTT. The blots were first blocked with 5% nonfat dry milk in PBS and then probed with a primary antibodies. 293F supernatants from cells expressing 14E1 and 14E1A were probed with a goat anti-mouse IgG (H þ L) antibody conjugated with horseradish peroxidase (HRP; EMD). Mouse tibialis muscle lysate samples were probed with an anti-Etag antibody conjugated with HRP (GE Healthcare). As a loading control, tibialis lysate was also probed with primary goat anti-actin antibody (Santa Cruz Biotechnology, Santa Cruz, CA) and secondary mouse anti-goat IgG conjugated with HRP (Pierce, Rockford, IL). The blots were then treated with the ECL Western Blotting Analysis System (GE Healthcare). For detection of protein bands, the blots were exposed to Biomax Light Film (Kodak, Rochester, NY).
Cell growth inhibition A431 cells were seeded into 12-well plates at a density of 7.5 Â 10 4 cells per well in 0.5% fetal bovine serum DMEM. Cells were treated with purified 14E1A and 14E1 antibody at varying concentrations. Control cells were treated with the equivalent volume of PBS. Cells were allowed to grow for 72 h at which time the viable cell mass was measured by a MTS assay using the CellTiter 96 AQ ueous Non-Radioactive Cell Proliferation Assay (Promega, Madison, WI). After a 90 min incubation with the MTS reagent, the optical density at 490 nm was measured for each well using a microplate reader.
ELISA
The 14E1 and 14E1A antibody levels were determined using an enzyme-linked immunosorbent assay (ELISA) assay. 96 well Immulon 4 HBX (Nunc, Rochester, NY) were coated overnight with either EGFR extracellular domain 22 at 200 ng per well (for functional 14E1) or goat anti-Etag antibody (Bethyl Laboratories, Montgomery, TX, for both 14E1 and 14E1A) at 100 ng per well, in 0.01 M bicarbonate buffer, pH 9.5, 55 ml per well. Plates were blocked with 1% bovine serum albumin (BSA; Sigma, St Louis, MO) and then incubated with dilutions of mouse serum, in PBS (Invitrogen) with 0.5% Tween-20 (Bio-Rad, Hercules, CA), 1% BSA (PBSTB). Subsequent serial dilutions were made in PBSTB plus 0.2% naive mouse serum (PBSTB þ ms). Purified full-length 14E1-Etag antibody diluted in 0.2% naive mouse serum served as the positive control and standard (1000-1.4 pg ml À1 ) for all 14E1 plates, whereas purified ablated full-length 14E1-Etag antibody diluted in 0.2% naive mouse serum served as the positive control and standard (2000-0.49 pg ml
À1
) for all ablated 14E1 plates. Diluted samples and standards were incubated for 1-2 h at room temperature, washed 4 Â in PBST, then incubated for 1 h at room temperature with either mouse monoclonal anti-Etag HRP secondary antibody (GE Healthcare) diluted 1:8000 in PBST (for functional 14E1), or with goat anti-mouse IgG HRP (Santa Cruz Biotechnology) diluted 1:2500 in PBSTB (for both functional and ablated 14E1 in a sandwich ELISA). Plates were then washed 4 Â and developed in 2,2'-azino-bis(3-ethylbenzthiazoline-6-sulphonic acid (Sigma-Aldrich, St Louis, MO) for approximately 10 min. All plates were read at A405 and analyzed using SOFTmax Pro. Data were graphed in Excel.
Mouse model studies
Male nu/nu mice were obtained from Simonsen (Gilroy, CA) and 5-to 9-week-old mice were injected intramuscularly, at times differing by group, with either AAV2/1-14E1 or AAV2/1-14E1A, bilaterally with a total dose of 1 Â 10 11 or 5 Â 10 11 genome content (GC) in 150 ml PBS, and 25 ml was injected into the tibialis muscle and 50 ml into the gastrocnemius muscle of each hind limb (total 75 ml per one hind limb). When animals underwent tumor challenge, A431 cells were injected at day 0, and each animal was injected subcutaneously in the right flank with 2-5 Â 10 6 cells. Mice were bled periodically via the tail vein. All mice were treated according to the Institute for Laboratory Animal Research Guide for the Care and Use of Laboratory Animals, and housed under specific pathogen-free conditions. Tumors were measured using electronic calipers, by taking a length measurement and a width measurement perpendicular to each other. Tumor volume was calculated by the following formula: (length Â width 2 ) Â p/6 and reported in mm 3 . Animals were killed when tumors reached 43000 mm 3 or appeared to be in distress. Tumor volume and animal weight were measured weekly, and survival was monitored. The tumor growth portion of the study was ended when 430% of both the tumor only and ablated control groups' mice required to be killed due to tumor volume. Survival continued to be monitored. Because the treated animals in the tumor studies appeared to be in no distress, they were monitored past the end of the survival study to track regression. Survival was analyzed with GraphPad Prism5 using a Kaplan-Meier curve and Mantel-Cox log-rank test. P-values were calculated by comparison against both the tumor only and the ablated control.
Immunohistochemistry
Mouse tibialis muscles were harvested from a naive nude mouse and study mice injected with AAV2/1-14E1 and AAV2/1-14E1A. The muscles were harvested 84 days postinjection, washed with PBS and immersed in 10% formalin solution. The muscle tissue was sent to PhenoPath Laboratories (Seattle, WA) for paraffin embedding and subsequent immunohistologic analysis. Briefly, sectioned tissue samples were deparaffinized, pretreated with Protease Type XXIV (Sigma-Aldrich, catalog no. P8038), incubated with a rabbit anti-Etag antibody (Bethyl Laboratories) and then sequentially incubated with the Rabbit Envision þ system and DAB þ substrate (Dako, Carpinteria, CA). The slides were then counterstained with Meyer's hematoxylin, dehydrated and coverslipped.
A431 xenograft tumor samples were harvested, washed with PBS, immersed in 10% formalin solution and delivered to PhenoPath Laboratories for paraffin embedding and subsequent immunohistologic analysis. Samples were stained for Etag as described above.
Results
In vitro expression and anti-EGFR activity of 14E1 and 14E1A antibodies 14E1 is a murine IgG1 antihuman EGFR antibody that competes with the growth factors EGF and transforming growth factor-a for binding to the extracellular domain of the EGF receptor. [22] [23] [24] 14E1 has been shown to suppress EGFR activation and significantly inhibit the growth of carcinoma cells overexpressing EGFR. 23, 24 14E1 shares similar characteristics with other EGFR-blocking antibodies, including the murine IgG1 225, which have demonstrated efficacy against xenograft tumor models. 25, 26 Collectively, these results supported the hypothesis that 14E1 would similarly function as an effective antiproliferative antibody against A431 vulvar carcinoma cells that overexpress EGFR. Therefore, 14E1 was chosen as a model antibody to evaluate in vivo expression of a full-length antibody and efficacy against the A431 xenograft tumor model following delivery by AAV.
The heavy and light chains of 14E1 were linked together by the Furin/2A sequence and cloned into the AAV shuttle vector pZAC2.1 (Figure 1a) . The Furin/2A sequence includes the cleavage site for the protease Furin linked to the 2A self-processing peptide (Figure 1a) . The presence of both elements in the Furin/2A sequence allowed for the monocistronic expression of separate heavy and light chains.
To provide a negative control murine IgG1 antibody, the 14E1 antibody was mutated at critical residues to ablate anti-EGFR activity. There are three CDRs in each of the variable heavy and variable light domains that are critical for antibody recognition and binding to the antigen. To ablate binding, amino-acid residues in the CDR3 for both the heavy and light chains of 14E1 were substituted with alanine to construct the control antibody 14E1A (Figures 1b and c) .
The 14E1 Etag -pZAC and 14E1A Etag -pZAC plasmid constructs were transiently transfected into 293F cells for in vitro expression of the respective antibodies. Supernatants from the transfections were collected after 4 days and analyzed by western blot using a goat antimouse IgG (H þ L)-HRP-conjugated antibody. The samples were analyzed under both reducing and nonreducing SDS-PAGE conditions. Under nonreducing conditions for both 14E1 and 14E1A, a prominent band was detected at approximately 160 kDa as expected for a complete full-length antibody (Figure 2a) . Under reducing conditions, two bands corresponding to the heavy chain at B55 kDa and the light chain at B25 kDa were detected for both 14E1 and 14E1A (Figure 2b) .
To confirm the ability of 14E1 to bind EGFR, the 14E1 transient transfection supernatant was analyzed by ELISA. 14E1 antibody bound EGFR in the ELISA, and the antibody concentration in the supernatant was determined to be approximately 7.5 mg ml À1 (data not shown). The control antibody 14E1A was unable to bind EGFR, confirming that the mutations to the CDR3 region successfully ablated function (data not shown).
The 14E1 antibody protein was evaluated for the ability to inhibit the proliferation of A431 cells in vitro. A431 cells were cultured in the presence of increasing concentrations of 14E1 or the control 14E1A antibodies, and cell viability was measured after 3 days. As predicted by the results of the aforementioned anti-EGFR ELISA, the presence of the control antibody 14E1A did not significantly affect the growth of A431 cells when compared to control PBS-treated cells (Figure 3) . The 14E1 antibody significantly inhibited the proliferation of the A431 cells in a dose-dependent manner with a maximum inhibition of B40% at a concentration of 0.75 mg ml À1 (Figure 3 ). This inhibition of A431 proliferation, which plateaus at higher antibody concentrations, is consistent with earlier results reported with other EGFR antibodies, including the experimental antibodies 225 (the ), 25 528 (plateau of 60% inhibition at 2.5 mg ml À1 ) 27 and the commercial antibody E7.6.3/ panitumumab with a plateau of 60% inhibition at approximately 0.15 mg ml À1 . 28 Therefore, we proceeded to evaluate the 14E1 antibody in vivo.
In vivo expression of 14E1 antibody following delivery by AAV2/1
The 14E1 Etag -pZAC and 14E1A Etag -pZAC plasmid constructs were used for production of the pseudotype AAV2/1-14E1 and AAV2/1-14E1A. The pseudotype vector AAV2/1, containing the AAV2 ITR and rep with the cap from AAV1, was chosen for maximal expression in murine skeletal muscle. [29] [30] [31] To determine whether expression levels of the control 14E1A were similar to the levels of 14E1 in the tibialis muscle following AAV delivery, immunohistochemistry (IHC) was performed on muscle sections to detect the presence of the antibodies by staining for Etag. Separate groups of athymic nude mice were injected intramuscularly into the hind limb with a single dose of 1 Â 10 11 vector particle (vp) per mouse of either AAV2/1-14E1 or AAV2/1-14E1A. At 84 days postinjection, similar staining levels of 14E1 and 14E1A were detected in the mouse tibialis muscle by IHC (Figure 4a ). To provide further qualitative evidence for comparable expression levels of both antibodies, wholecell lysates from 84-day postinjection tibialis muscles were also subjected to western analysis (Figure 4b) , where comparable levels of antibody expression for both antibodies can be seen, supporting the IHC results.
To quantitatively determine levels of 14E1 in the serum over time, athymic nude mice were injected intramuscularly with a single dose of AAV2/1-14E1 in the hind limb at 1 Â 10 11 GC per mouse. Serum samples were collected periodically and levels of functional 14E1 were determined using an anti-EGFR ELISA. The delay in transgene expression after AAV administration is well recognized and levels of 14E1 were relatively low (B5.5 mg ml À1 ) at 7 days postinjection (Figure 4c ). Serum levels of 14E1 steadily climbed starting 7 days after AAV injection and peaked at over 1000 mg ml À1 by day 56 postinjection (Figure 4c ). Although 14E1 levels gradually declined after day 56, levels greater than 600 mg ml À1 were still detected in the serum at day 84. To confirm that serum levels of 14E1A antibody were comparable to 14E1 antibody over time, a separate group of athymic nude mice were injected intramuscularly with AAV2/1-14E1A in the same manner. The serum levels of 14E1A over time were not significantly different from the 14E1 results (Figure 4d ) for at least 56 days postinjection of AAV.
Localization of 14E1 antibody to A431 xenograft tumors
To demonstrate the localization of the 14E1 antibody to the A431 xenograft tumor, IHC was performed on tumors harvested from mice treated with AAV2/1-14E1 and AAV2/1-14E1A as well as tumor only. Tumor sections were stained for Etag to probe for the presence of 14E1 and 14E1A antibody. As expected, no Etag staining could be detected in the tumor only sample (Figure 5a ). With the exception of blood vessel staining, the control 14E1A did not localize to the tumor tissue (Figure 5a ). Given the high serum levels of 14E1A at the time of tumor harvest, the staining within the blood vessels was anticipated. Thus, the 14E1A antibody serves as a valid, nonfunctional control for the 14E1 antibody in subsequent in vivo experiments. In contrast, 14E1 exhibited very strong and uniform staining to the plasma membrane of viable A431 tumor tissue (necrotic tumor tissue could not stain; Figure 5a ) and colocalized with the staining for human EGFR (data not shown).
14E1 antibody expression following delivery by AAV demonstrates antitumor efficacy
Upon achieving high and sustained levels of full-length antibody expression in the mice, we investigated whether AAV-delivered 14E1 antibody is capable of antitumor efficacy against the A431 xenograft tumor model. On the basis of the serum levels of 14E1 over time following intramuscular AAV administration (Figure 4b ), AAV2/1-14E1 was injected intramuscularly into athymic nude mice at different time points relative to A431 tumor challenge (Figure 5b ). To allow sufficient time for significant serum levels of 14E1 at tumor challenge, AAV2/1-14E1 (1 Â 10 11 GC per mouse) was injected at day À28 relative to the day of tumor challenge (day 0, 2 Â 10 6 A431 cells injected subcutaneously into the right flank). As significant circulating levels of 14E1 were expected in the À28 day group at the time of tumor challenge (approximately 600 mg ml À1 ), this 14E1 treatment group was predicted to prevent tumor growth, and served as the positive control for the subsequent AAV injection times closer to, and beyond, the time of tumor challenge. To serve as a negative control for all groups, AAV2/1-14E1A (5 Â 10 11 GC per mouse) was administered to a separate experimental group of mice at the same time. 
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To investigate whether expression of 14E1 following AAV delivery could significantly inhibit early-stage A431 tumors, AAV2/1-14E1 was administered for one experimental group of mice at day þ 1 and a separate group at day þ 7 (5 Â 10 11 GC per mouse for both groups). By day 7 after tumor challenge, all animals in the study had measurable tumors, with an average tumor volume (excluding positive control) of 55.5 mm 3 . The positive control group (AAV2/1-14E1 injected at day À28) had an average tumor volume of 32.6 mm 3 at day 7. For both the groups injected with AAV2/1-14E1 at days þ 1 and þ 7, significant inhibition of tumor growth was observed for the treated mice compared against both tumor only and ablated antibody controls by day 35 (Pp0.002 for both groups, when compared against either control). The negative control AAV2/1-14E1A did not show any significant effect on tumor growth relative to the untreated tumors (P ¼ 0.87; Figure 5c ). Treatment with 14E1 at an earlier stage of tumor growth significantly decreased average tumor volumes as seen in the comparison between groups days þ 1 and þ 7 (P ¼ 0.008; Figure 5c ). Tumor volumes for the days þ 1 and þ 7 groups were not only significantly inhibited by treatment with AAV2/1-14E1 but the average tumor volumes also appeared to plateau by about day þ 35 (Figure 5c ). As shown by the day À28 group, high serum levels of the 14E1 antibody at the time of tumor injection significantly prevented the enlargement of tumors (Figure 5c ).
The significant inhibition of tumor growth resulted in dramatically improved survival time for all three 14E1 treatment groups (Figure 5d ). For the tumor only and 14E1A control groups, the median survival time was approximately 42 days (Figure 5d ). Strikingly, all three 14E1 treatment groups exhibited 100% survival till the end of the study at day 72 (Po0.0001; Figure 5d ). Beyond the end of the survival study, remaining mice were monitored for potential tumor regression. In the day À28 group, 12 of the 13 mice exhibited complete inhibition of tumor growth (no tumor burden) by day 64, with 100% of remaining mice showing complete regression by day 100 (one mouse from the group, with no tumor burden remaining, was killed in the interim as a Figure 4 Expression of 14E1 and 14E1A antibody in mouse serum and hind limb muscle following delivery by adeno-associated virus (AAV) 2/1 (a) Athymic nude mice were given a single, bilateral intramuscular (i.m.) injection of AAV2/1-14E1 or AAV2/1-14E1A into the tibialis and gastrocnemius muscle. Tibialis muscle sections were prepared 84 days after injection and examined by immunohistochemical staining for Etag. Magnification, Â 200. (b) Western blot analysis of whole-cell lysates prepared from the tibialis muscle of nude mice injected with AAV2/1-14E1 or AAV2/1-14E1A. The lysates were separated by SDS-polyacrylamide gel electrophoresis (PAGE) and probed with a rabbit anti-Etag antibody conjugated to horseradish peroxidase (HRP) for detection of 14E1 and 14E1A. As a loading control, the same lysates were also probed with a goat anti-actin antibody. Each sample is a pool of the left and right hind limb tibialis muscles from 10 mice. (c) AAV2/1 14E1 Etag -pZAC was injected i.m. into mice, into both the tibialis and gastrocnemius of each hind limb of each animal, with a total dosage of 1 Â 10 11 genome content (GC) per mouse. Serum 14E1 antibody levels were determined using an HRP-conjugated rabbit anti-Etag antibody enzyme-linked immunosorbent assay (ELISA) with epidermal growth factor receptor (EGFR)-coated plates (mean±s.e.m., n ¼ 10). (d) Either AAV2/1-14E1 or AAV2/1-14E1A was injected i,m. into mice, into both the tibialis and gastrocnemius of each hind limb of each animal, with a total dosage of 1 Â 10 11 GC per mouse. Serum 14E1 and 14E1A antibody levels were determined using a sandwich ELISA with anti-Etag-coated plates and developed with HRP-conjugated goat anti-mouse immunoglobulin G (IgG; mean±s.e.m., n ¼ 10).
Established tumor inhibited by a-EGFR Ab from AAV DT Ho et al result of nonstudy-related injuries). These animals continued to be monitored until day 127, and there was no evidence of tumor recurrence by that time. For the day þ 1 group, 4 of the 15 mice exhibited complete regression of tumor growth by day 127. Considerable regression of tumor volume was also measured for the day þ 7 group with 4 of the 11 mice regressing at least 700 mm 3 by day 134 (regression data not shown).
With the successful inhibition of early-stage tumors by AAV2/1-14E1 injection up to day þ 7, the next experiment aimed to understand whether well-established tumors could be inhibited by AAV-expressed 14E1 antibody. AAV injections were performed at days þ 13 and þ 20 relative to tumor challenge (Figure 6a ). On the basis of the previous experiment, the lead time for the positive control was reduced, with AAV2/1-14E1 (1 Â 10 11 GC per mouse) injected intramuscularly at day À7 and the negative control, AAV2/1-14E1A (5 Â 10 11 GC per mouse) was also injected at day À7. The positive control day À7 group significantly prevented tumor growth (Figure 6b ) and exhibited considerable tumor regression during the course of the study with 10 of the 13 mice showing complete regression by day 85 (regression data not shown). The average tumor volume of the þ 13 and þ 20 groups at the time of injection (AAV2/1-14E1, 5 Â 10 11 GC per mouse) was 99 and 413 mm 3 , respectively. In both the days þ 13 and þ 20 groups, tumor growth was significantly inhibited by treatment with the AAV2/1-14E1 by day 43 (Po0.04 against both tumor only and ablated antibody control groups; Figure 6b ) and resulted in significantly enhanced survival versus the tumor alone group (Po0.03) or the ablated control group (Po0.05) Figure 5 Adeno-associated virus (AAV) 2/1-mediated delivery of 14E1 inhibits the growth of early-stage tumors and prolongs survival. (a) Localization of the 14E1 antibody to the A431 xenograft tumor. A431 xenograft tumors were implanted by subcutaneous injection at day 0. AAV2/ 1-14E1A was injected before tumor challenge at day À28 and AAV2/1-14E1 was injected after tumor challenge at day þ 7. At day 62, tumors were harvested and prepared for immunohistochemical staining with anti-Etag. Magnification, 400 Â . (b) AAV2/1-14E1 injections were performed at À28 days, þ 1 day, þ 7 days and AAV2/1-14E1A injections were performed at À28 days, all relative to tumor injection. In groups þ 7 days and þ 1 day (n ¼ 11 and 15, respectively), mice were injected intramuscularly with AAV2/1-14E1, with a total dosage of 5 Â 10 11 genome content (GC) per mouse at 7 days and 1 day, respectively, after the injection of tumor cells. One group (À28 days positive control, n ¼ 13) of mice was injected intramuscularly with AAV2/1-14E1, with a total dosage of 1 Â 10 11 GC per mouse, 28 days before the injection of tumor cells. The À28 days ablated control group of mice (n ¼ 13) was injected intramuscularly with AAV2/1-14E1A with a total dosage of 5 Â 10 11 GC per mouse, also 28 days before the injection of tumor cells. The final group, the tumor only control, (n ¼ 11) was not injected with AAV. All 5 groups were injected with 2 Â 10 6 A431 cells; this was regarded as day 0. (c) Tumor volumes were measured weekly (mean ± s.e.m.), and P-values were calculated by comparison against the tumor only (value shown) and ablated control groups (all p0.0002). (d) Survival was monitored for all groups. P-values were calculated by comparison against the tumor only and ablated control groups (*value shown is the same for all test groups and the positive control when compared against either tumor only control or ablated control).
by day 56 (Figure 6c ), demonstrating that AAV-expressed antibody could inhibit the growth of well-established tumors.
Discussion
In this study, we were able to achieve high and sustained serum levels of full-length 14E1 mAb in nude mice following intramuscular injection of AAV2/1 by incorporating the previously developed Furin/2A technology. 21, 32, 33 Serum levels of 14E1 peaked at over 1000 mg ml À1 at day 56 postinjection and persisted at levels greater than 600 mg ml À1 for over 4 months. Administration of AAV2/1-14E1 prior to tumor challenge resulted in significant inhibition of tumor growth, prolonged survival time and tumor regression. Importantly, when AAV was administered up to 20 days after tumor challenge, 14E1 was capable of significant growth inhibition of well-established tumors and prolonged survival time.
Therapeutic efficacy against well-established tumors has several ramifications for the gene-based delivery of antibodies. For example, when evaluating candidate antibodies, the ability to administer AAV after the tumor has been established helps to circumvent issues with tumor cell lines that have a low take rate. When AAV is administered prior to tumor challenge, the ability to differentiate between a mouse cured of tumor burden as a result of treatment versus a mouse that did not have a tumor properly 'take' is difficult. Furthermore, the ability to treat established tumors allows for a larger window for the evaluation of candidate antibody efficacy. From a clinical perspective, inhibition of a well-established tumor is clearly more relevant and demonstrates the potential of gene-based delivery of antibodies as a therapeutic treatment.
The 14E1 antibody inhibits the proliferation of A431 cells through the same mechanisms as the well-studied antibody 225. Both 14E1 and 225 are murine IgG1 antibodies that bind to the same or overlapping epitopes on human EGFR, blocking ligand-dependent activation [22] [23] [24] 26, 34 and promoting receptor dimerization without activation, resulting in subsequent downregulation of EGFR, 35 and are not likely to initiate significant antibody-dependent cellular cytotoxicity nor complementmediated lysis in the xenograft model. 36, 37 For early-stage A431 tumors, a significant portion of tumors regressed in tumor volume following 14E1 treatment. This effect was more pronounced than treatment of well-established tumors where tumor growth was arrested but did not significantly regress.
The only previously reported example of efficacious delivery of a full-length mAb by AAV was administered by intravenous injection in the mouse tail vein 24 days prior to tumor challenge with pseudotype AAV2/8.
21
AAV2/8 is capable of transducing many different tissues, most efficiently the liver. 38 Instead of intravenous delivery, here we demonstrated efficacy via localized delivery of AAV2/1 into the hind limb muscles. Of the 12 known AAV serotypes, AAV2/1 is perhaps the optimal serotype for transduction of skeletal muscle tissue. [29] [30] [31] 39 When comparing equal amounts of viral genomes per animal in nude mice, we achieved 14E1 serum levels very similar to those achieved with the rat mAb DC101 using AAV2/8. 21 Both approaches appear to result in systemic, efficacious levels of antibody. However, intravenous delivery of AAV2/8 may lead to transduction of unintended tissues and thus may require tissue-specific promoters.
For preclinical antibody research, the delivery of antibodies by AAV may provide a rapid and improved option for in vivo validation of antibody leads. With improved and standardized production of AAV, the ability to efficiently produce AAV for an antibody may provide a time, labor and cost-effective alternative to the expression and purification required for a protein delivery approach. During the time needed to express and purify milligram quantities of a few candidate antibodies, multiple candidate antibody AAV could be produced and available for in vivo evaluation of safety and efficacy.
In this study, we have demonstrated proof of concept for the delivery of efficacious levels of a murine antibody in nude mice. To continue progressing toward clinical application, the delivery of full-length antibodies by AAV will likely require a regulated system for antibody expression. An inducible gene-expression system that can tightly modulate the circulating levels of mAbs to therapeutic levels is highly desirable. Furthermore, an inducible gene-expression system would enable the clinician to stop gene expression at the end of treatment or for any potential safety reasons. Many different smallmolecule-regulated gene-expression systems have been developed and incorporated into AAV delivery systems including those induced by tetracycline, Rapamycin and mifepristone. 40, 41 Recently, Fang et al. 32 demonstrated regulated expression of a full-length antibody following AAV delivery by incorporating the Furin/2A technology with a dual vector Rapamycin system. Further improvements for a gene-regulated AAV system for antibodies could include the incorporation of a one-vector system versus a dual-vector system. A one-vector system could ensure that the complete regulation system is delivered to transduced cells as well as simplifying manufacturing. Recent work has validated a one-plasmid mifepristone system for regulated expression of interferon following delivery by AAV and demonstrated long-term, inducible expression of interferon for nearly 1 year. 42 Although demonstrated for smaller genes such as interferon, the gene-regulated expression of a full-length antibody from a one-vector system using AAV will pose a challenge given the size limitations of the AAV vector.
In summary, we have advanced and expanded the utility of AAV to deliver efficacious levels of a full-length antibody against a xenograft tumor model. To our knowledge, this is the first demonstration of the inhibition of an established tumor by a full-length antibody delivered by AAV. The gene-based delivery of full-length antibodies is a promising approach for preclinical applications such as the in vivo validation of candidate antibodies. With further improvements, the delivery of therapeutic antibodies by AAV could make an impact as a novel form of antibody therapy.
